Lund, Sweden — 29 January 2021 — During January 2021, 1,300 subscription warrants in Camurus’ subscription warrant series 2017/2020 have been exercised and as a consequence the number of shares and votes has increased by 1,417. Prior to the exercise, the total number of shares in Camurus amounted to 54,233,773, corresponding to 54,233,773 votes. As of 29 January 2021, the total number of shares in Camurus amounts to 54,235,190, corresponding to 54,235,190 votes.
For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92
Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of cancer, endocrine diseases, pain and addiction, which are developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com.
The information is such that Camurus AB is obliged to make public pursuant to Chapter 4, Section 9 of the Swedish Financial Instruments Trading Act. The information was submitted for publication on 29 January 2021 at 7:00 AM CET.